Skip to main content
← Back to Science Explained

Research limits

Keep the open questions visible

Good science has edges. These articles name what is known, what is still being studied, and where confident claims move faster than evidence.

Read with discipline

01Known evidence
02Open variables
03Claims to pause

Read the open questions

  1. 01GLP-1 reaches brain circuits beyond appetiteBeyond appetite. Inflammation. Mood. Alcohol. Bone.
  2. 02The same GLP-1 dose produces different results in different peopleTwo patients on identical GLP-1 doses can lose dramatically different amounts of weight. One might lose 8 percent of their body weight while another loses 22 percent. The difference is not random, and it is not about willpower.
  3. 03Years on GLP-1 leave marks on the brain we are still mappingMost clinical trials for GLP-1 peptides run under two years. That is the timeframe we have data for. That is also the limit of what we know.
  4. 04Lower maintenance doses may hold the weight after the lossThe most sobering fact about GLP-1 agonists is simple: most patients who stop taking them regain the majority of lost weight. The weight returns within months or a year. This is biology reasserting itself. But it raises a hard question.
  5. 05GIP and glucagon add new levers the newest peptides pullGLP-1 drugs produce average weight loss around 15 percent. Tirzepatide reaches 22.5 percent. Retatrutide reached 24.2 percent in Phase 2 and 28.7 percent in Phase 3 TRIUMPH-4. Each generation activates more pathways.
  6. 06Gut bacteria and GLP-1 run a two-way feedback loopThe gut is home to trillions of bacteria that shape how the body works. They influence digestion, immune function, mood, and metabolism. GLP-1 peptides reshape that microbial landscape, and the reshaped landscape feeds back into the system.